Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.49 |
| ▸ | ACACB | O00763 | 9/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ACACA | Q13085 | 5/20 | 0.46 |
| ▸ | CKS1B | P61024 | 1/20 | 0.45 |
| ▸ | SKP1 | P63208 | 1/20 | 0.45 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4377073 | 0.88 | KMT2A (0.56) | DRD2ACACBKMT2AACACACKS1B | |
| SCHEMBL3816616 | 0.88 | KMT2A (0.56) | DRD2ACACBKMT2AACACACKS1B | |
| SCHEMBL190838 | 0.88 | KMT2A (0.56) | DRD2ACACBKMT2AACACACKS1B | |
| SCHEMBL3942686 | 0.88 | KMT2A (0.56) | DRD2ACACBKMT2AACACACKS1B | |
| SCHEMBL3381120 | 0.86 | ACACB (0.50) | DRD2ACACBKMT2AACACACKS1B | |
| SCHEMBL27840928 | 0.84 | ACACB (0.45) | DRD2ACACBKMT2AACACACKS1B | |
| Bicarbonate SCHEMBL1580718 | 0.84 | KMT2A (0.57) | DRD2ACACBKMT2AACACACKS1B | |
| SCHEMBL228180 | 0.84 | EPHX1 (0.50) | DRD2ACACBKMT2AACACACKS1B | |
| Formaldehyde SCHEMBL28082239 | 0.84 | KMT2A (0.54) | DRD2ACACBKMT2AACACACKS1B | |
| SCHEMBL10209101 | 0.84 | EPHX1 (0.54) | DRD2ACACBKMT2AACACACKS1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339904-A1 | ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2023-10-26 | — | — | US | claimed |
| US-20230339904-A1 | ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2023-10-26 | — | — | US | disclosed |
| CN-102036659-A | PGI2 receptor modulators for the treatment of prostacyclin receptor-related disorders | ARENA PHARM INC | 2011-04-27 | — | — | CN | disclosed |
| EP-1534700-A1 | NOVEL THIOPHENE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | WARNER-LAMBERT COMPANY LLC (US) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004018448-A1 | NOVEL THIOPHENE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | WARNER-LAMBERT COMPANY LLC (US) | 2004-03-04 | — | — | WO | disclosed |
| EP-0871436-A4 | USE OF Stat 6 SH2 DOMAIN SPECIFIC COMPOUNDS TO TREAT ALLERGIC REACTIONS | SMITHKLINE BEECHAM CORP (US) | 1999-10-20 | — | — | EP | disclosed |
| EP-0809490-A4 | USE OF LCK SH2 SPECIFIC COMPOUNDS TO TREAT AUTOIMMUNE DISEASES AND ALLOGRAFT REJECTION | SMITHKLINE BEECHAM CORP (US) | 1999-10-20 | — | — | EP | disclosed |
| EP-0835104-A4 | USE OF STAT 5 SH2 DOMAIN SPECIFIC COMPOUNDS TO ENHANCE ERYTHROPOIESIS | SMITHKLINE BEECHAM CORP (US) | 1999-10-20 | — | — | EP | disclosed |
| EP-0614911-B1 | Compounds having a sulfonamide and an amidinegroup, process for preparation and pharmaceutical compositions comprising them | SANOFI SA (FR) | 1999-04-28 | — | — | EP | disclosed |
| EP-0871436-A1 | USE OF Stat 6 SH2 DOMAIN SPECIFIC COMPOUNDS TO TREAT ALLERGIC REACTIONS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-10-21 | — | — | EP | disclosed |
| EP-0835104-A1 | USE OF STAT 5 SH2 DOMAIN SPECIFIC COMPOUNDS TO ENHANCE ERYTHROPOIESIS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-04-15 | — | — | EP | disclosed |
| EP-0809490-A1 | USE OF LCK SH2 SPECIFIC COMPOUNDS TO TREAT AUTOIMMUNE DISEASES AND ALLOGRAFT REJECTION | SMITHKLINE BEECHAM CORPORATION (US) | 1997-12-03 | — | — | EP | disclosed |
| WO-1997002023-A1 | USE OF Stat 6 SH2 DOMAIN SPECIFIC COMPOUNDS TO TREAT ALLERGIC REACTIONS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-01-23 | — | — | WO | disclosed |
| WO-1997002024-A1 | USE OF STAT 5 SH2 DOMAIN SPECIFIC COMPOUNDS TO ENHANCE ERYTHROPOIESIS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-01-23 | — | — | WO | disclosed |
| EP-0728482-A2 | Use of hcp specific compounds to enhance erythropoiesis | SMITHKLINE BEECHAM CORPORATION (US) | 1996-08-28 | — | — | EP | disclosed |
| EP-0727211-A1 | Use of src SH2 specific compounds to treat a bone resorption disease | SMITHKLINE BEECHAM CORPORATION (US) | 1996-08-21 | — | — | EP | disclosed |
| WO-1996024343-A1 | USE OF LCK SH2 SPECIFIC COMPOUNDS TO TREAT AUTOIMMUNE DISEASES AND ALLOGRAFT REJECTION | SMITHKLINE BEECHAM CORPORATION (US) | 1996-08-15 | — | — | WO | disclosed |
| EP-0614911-A1 | Compounds having a sulfonamide and an amidinegroup, process for preparation and pharmaceutical compositions comprising them | SANOFI (FR) | 1994-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339904-A1 | ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | CSNK1A1, CSNK1D, CSNK1G1 | DRD2 2393/4885ACACB 2649/4885KMT2A 3064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.